HOME >> MEDICINE >> NEWS
GroPep starts Phase 1 infertility trial

GroPep's program - to develop a treatment for a condition that potentially causes 50% of all miscarriages - reached a major milestone today with commencement of recruitment of healthy women volunteers into a Phase 1 trial of its infertility drug, PV903.

The drug is targeted to treat recurrent miscarriages caused by an abnormal immune response to the foetus a condition for which there is no current treatment.

The market for a drug to treat this condition is estimated to be up to US$750 million annually.

Listed biopharmaceutical company GroPep Limited (ASX:GRO) announced today that it will commence a Phase 1 trial of its infertility drug PV903. The trial, which will be conducted under the Therapeutic Goods Administration Clinical Trial Notification scheme, was approved by the Royal Adelaide Hospital Research Ethics Committee.

Recruitment will begin immediately to allow medical screening and enrolment of the first cohort of subjects in mid-February 2006. The results of the trial should be known in late 2006, depending on recruitment rate.

The trial, conducted at the CMAX Adelaide-based facilities, involves healthy female volunteers each receiving a single administration of PV903 gel (or placebo) as they are enrolled sequentially into three groups with the PV903 dose escalating between groups. A total of 36 volunteers will complete the trial. The objectives of the trial are to evaluate the safety and tolerability of vaginally administered PV903 gel, and to determine whether PV903 has effects on vaginal immune cells in a manner consistent with its proposed role in treating immunebased infertility.

Over 50% of miscarriages have no apparent explanation and some scientists believe that women who suffer from repeated miscarriage have an immune system that attacks the embryo as "foreign". PV903 is a recombinant version of a protein that is naturally found in semen and thought to be re
'"/>

Contact: Mr Tony Mitchell
61-283-547-700
Research Australia
9-Jan-2006


Page: 1 2

Related medicine news :

1. GroPep awarded key patent for infertility treatment in Europe
2. GroPep completes final milestone of the path malaria vaccine initiative
3. GroPep to pursue promising asthma drug following preclinical study results
4. GroPep licenses technology to TGR BioSciences
5. GroPep news: Key psoriasis patent granted in Japan and new asthma patent filed for GroPep drug
6. Coffee jump-starts short-term memory
7. Epidemiology in Europe: the problem starts in childhood
8. GSK announces launch of largest ever Phase III trial in lung cancer treatment
9. Phase II study shows combination improves survival of metastatic melanoma patients
10. MacroChem completes patient enrollment for Phase II trial of EcoNail for treatment of onychomycosis
11. Drug combination proves effective against myeloma in Phase I trial

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/17/2019)... , ... April 17, 2019 , ... ... advice. However, recently, this reluctance appears to be changing. Whether because of demographic ... at least, probe their healthcare providers advice. , In the past, efforts to ...
(Date:4/17/2019)... ... April 17, 2019 , ... Ramneek Kumar Talwar and Vineet ... Gwangju, Korea, and has highly evaluated and confirmed iRINGER’s technology, a product that’s ... discussion of a potential partnership since then. , After sharing relevant ...
(Date:4/17/2019)... ... April 17, 2019 , ... ... hangover symptoms. This California-made supplement was designed to lessen the negative effects ... available for purchase via GotPurpleTree.com and Amazon.com . , According ...
(Date:4/17/2019)... ... 17, 2019 , ... On May 3, Kyle Marcelli will return to ... the IMSA Continental Tire SportsCar Challenge race in 2018, Kyle Marcelli and ... drive their #60 KohR Motorsports / Roush Performance Ford Mustang GT4 across ...
(Date:4/17/2019)... ... April 17, 2019 , ... Cognition ... just released the second installment of their two-part white paper series discussing ISO ... new white paper reviews some of the high-level changes to the standard ...
Breaking Medicine News(10 mins):
(Date:4/18/2019)... (PRWEB) , ... April 18, 2019 , ... ... Florida Medical Association (FMA). The FMA is one of the country’s premier professional ... of Osteopathic Medicine in Florida. The FMA currently represents over 25,000 members on ...
(Date:4/18/2019)... (PRWEB) , ... April 18, 2019 , ... ... Lyme and other tick-borne diseases through research, education, and awareness, and Ranger Ready ... on building awareness of the importance of tick-bite prevention, including the proper use ...
(Date:4/17/2019)... ANGELES (PRWEB) , ... April 17, 2019 , ... Dr. ... University, has spent a large chunk of his career subverting ideas on creativity and ... suicide and depression , and now he’s ready to share his thoughts on social ...
Breaking Medicine Technology:
Cached News: